Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH11906 in advanced solid tumors
NCT05488821Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seratinib in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose up to 24 months and Recommended Phase II Dose up to 24 months. Status: unknown.
02
Drugs
seratinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05488821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488821.